Phase 4 Heart Disease Trial, Recruiting NCT05845489 Sponsor: Seoul National University Hospital Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT05845489
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 40 years or older, of any gender
  • People who have been found to have early-stage plaque buildup in the arteries of the heart (detected by a heart imaging scan called a coronary CT angiogram or coronary angiogram) within the past 2 years, without having had a heart-related event after that scan
  • People whose arteries are not blocked enough to require a procedure to open them up (less than 50% narrowing)
  • People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • People with a history of diagnosed heart or blood vessel disease, such as a heart attack, heart failure, disease in the leg arteries, stroke, mini-stroke (TIA), significant narrowing of the neck arteries (more than 50%), or a procedure on the neck arteries
  • People who have previously had a procedure or surgery to open or bypass heart arteries and as a result need to take blood-thinning (antiplatelet) medication long-term
  • People who are allergic to, or have a medical reason they cannot take, a medication called clopidogrel
  • People who are already taking blood-thinning (anticoagulant) medication for another health condition
  • People who have a history of a bleeding disorder, a clotting problem, or a serious bleeding episode that required them to stop taking antiplatelet medication
  • People who have a surgery or medical procedure planned that would require them to stop antiplatelet medication for one month or more
  • People who have a non-heart-related illness where their life expectancy is estimated to be 5 years or less at the time of joining the trial
  • People who are pregnant or breastfeeding
  • People whom the treating doctor considers to be unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Hyo-Soo Kim, MD, PhD, Seoul National University Hospital

Phone: 821026765736

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
22 March 2023
Est. completion
31 December 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Major adverse cardiovascular and cerebrovascular events (MACCE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov